Use of a Glycolipid Inhibitor to Ameliorate Renal Cancer in a Mouse Model

Subroto Chatterjee, Nezar Alsaeedi, Jennifer Hou, Veera Venkata Ratnam Bandaru, Lan Wu, Marc K. Halushka, Roberto Pili, Georges Ndikuyeze, Norman J. Haughey

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

In a xenograft model wherein, live renal cancer cells were implanted under the kidney capsule in mice, revealed a 30-fold increase in tumor volume over a period of 26 days and this was accompanied with a 32-fold increase in the level of lactosylceramide (LacCer). Mice fed D- threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol (D-PDMP), an inhibitor of glucosylceramide synthase and lactosylceramide synthase (LCS: β-1,4-GalT-V), showed marked reduction in tumor volume. This was accompanied by a decrease in the mass of lactosylceramide and an increase in glucosylceramide (GlcCer) level. Mechanistic studies revealed that D-PDMP inhibited cell proliferation and angiogenesis by inhibiting p44MAPK, p-AKT-1 pathway and mammalian target for rapamycin (mTOR). By linking glycosphingolipid synthesis with tumor growth, renal cancer progression and regression can be evaluated. Thus inhibiting glycosphingolipid synthesis can be a bonafide target to prevent the progression of other types of cancer.

Original languageEnglish (US)
Article numbere63726
JournalPLoS One
Volume8
Issue number5
DOIs
StatePublished - May 9 2013
Externally publishedYes

Fingerprint

kidney neoplasms
Glycosphingolipids
Kidney Neoplasms
glycolipids
Glycolipids
ceramide glucosyltransferase
Tumor Burden
Tumors
animal models
glycosphingolipids
Glucosylceramides
1-propanol
neoplasms
Sirolimus
Renal Cell Carcinoma
Heterografts
Capsules
Neoplasms
Cell Proliferation
Cell proliferation

ASJC Scopus subject areas

  • Medicine(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Agricultural and Biological Sciences(all)

Cite this

Chatterjee, S., Alsaeedi, N., Hou, J., Bandaru, V. V. R., Wu, L., Halushka, M. K., ... Haughey, N. J. (2013). Use of a Glycolipid Inhibitor to Ameliorate Renal Cancer in a Mouse Model. PLoS One, 8(5), [e63726]. https://doi.org/10.1371/journal.pone.0063726

Use of a Glycolipid Inhibitor to Ameliorate Renal Cancer in a Mouse Model. / Chatterjee, Subroto; Alsaeedi, Nezar; Hou, Jennifer; Bandaru, Veera Venkata Ratnam; Wu, Lan; Halushka, Marc K.; Pili, Roberto; Ndikuyeze, Georges; Haughey, Norman J.

In: PLoS One, Vol. 8, No. 5, e63726, 09.05.2013.

Research output: Contribution to journalArticle

Chatterjee, S, Alsaeedi, N, Hou, J, Bandaru, VVR, Wu, L, Halushka, MK, Pili, R, Ndikuyeze, G & Haughey, NJ 2013, 'Use of a Glycolipid Inhibitor to Ameliorate Renal Cancer in a Mouse Model', PLoS One, vol. 8, no. 5, e63726. https://doi.org/10.1371/journal.pone.0063726
Chatterjee S, Alsaeedi N, Hou J, Bandaru VVR, Wu L, Halushka MK et al. Use of a Glycolipid Inhibitor to Ameliorate Renal Cancer in a Mouse Model. PLoS One. 2013 May 9;8(5). e63726. https://doi.org/10.1371/journal.pone.0063726
Chatterjee, Subroto ; Alsaeedi, Nezar ; Hou, Jennifer ; Bandaru, Veera Venkata Ratnam ; Wu, Lan ; Halushka, Marc K. ; Pili, Roberto ; Ndikuyeze, Georges ; Haughey, Norman J. / Use of a Glycolipid Inhibitor to Ameliorate Renal Cancer in a Mouse Model. In: PLoS One. 2013 ; Vol. 8, No. 5.
@article{c83c901822f84e0ba823372d773e7c81,
title = "Use of a Glycolipid Inhibitor to Ameliorate Renal Cancer in a Mouse Model",
abstract = "In a xenograft model wherein, live renal cancer cells were implanted under the kidney capsule in mice, revealed a 30-fold increase in tumor volume over a period of 26 days and this was accompanied with a 32-fold increase in the level of lactosylceramide (LacCer). Mice fed D- threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol (D-PDMP), an inhibitor of glucosylceramide synthase and lactosylceramide synthase (LCS: β-1,4-GalT-V), showed marked reduction in tumor volume. This was accompanied by a decrease in the mass of lactosylceramide and an increase in glucosylceramide (GlcCer) level. Mechanistic studies revealed that D-PDMP inhibited cell proliferation and angiogenesis by inhibiting p44MAPK, p-AKT-1 pathway and mammalian target for rapamycin (mTOR). By linking glycosphingolipid synthesis with tumor growth, renal cancer progression and regression can be evaluated. Thus inhibiting glycosphingolipid synthesis can be a bonafide target to prevent the progression of other types of cancer.",
author = "Subroto Chatterjee and Nezar Alsaeedi and Jennifer Hou and Bandaru, {Veera Venkata Ratnam} and Lan Wu and Halushka, {Marc K.} and Roberto Pili and Georges Ndikuyeze and Haughey, {Norman J.}",
year = "2013",
month = "5",
day = "9",
doi = "10.1371/journal.pone.0063726",
language = "English (US)",
volume = "8",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "5",

}

TY - JOUR

T1 - Use of a Glycolipid Inhibitor to Ameliorate Renal Cancer in a Mouse Model

AU - Chatterjee, Subroto

AU - Alsaeedi, Nezar

AU - Hou, Jennifer

AU - Bandaru, Veera Venkata Ratnam

AU - Wu, Lan

AU - Halushka, Marc K.

AU - Pili, Roberto

AU - Ndikuyeze, Georges

AU - Haughey, Norman J.

PY - 2013/5/9

Y1 - 2013/5/9

N2 - In a xenograft model wherein, live renal cancer cells were implanted under the kidney capsule in mice, revealed a 30-fold increase in tumor volume over a period of 26 days and this was accompanied with a 32-fold increase in the level of lactosylceramide (LacCer). Mice fed D- threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol (D-PDMP), an inhibitor of glucosylceramide synthase and lactosylceramide synthase (LCS: β-1,4-GalT-V), showed marked reduction in tumor volume. This was accompanied by a decrease in the mass of lactosylceramide and an increase in glucosylceramide (GlcCer) level. Mechanistic studies revealed that D-PDMP inhibited cell proliferation and angiogenesis by inhibiting p44MAPK, p-AKT-1 pathway and mammalian target for rapamycin (mTOR). By linking glycosphingolipid synthesis with tumor growth, renal cancer progression and regression can be evaluated. Thus inhibiting glycosphingolipid synthesis can be a bonafide target to prevent the progression of other types of cancer.

AB - In a xenograft model wherein, live renal cancer cells were implanted under the kidney capsule in mice, revealed a 30-fold increase in tumor volume over a period of 26 days and this was accompanied with a 32-fold increase in the level of lactosylceramide (LacCer). Mice fed D- threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol (D-PDMP), an inhibitor of glucosylceramide synthase and lactosylceramide synthase (LCS: β-1,4-GalT-V), showed marked reduction in tumor volume. This was accompanied by a decrease in the mass of lactosylceramide and an increase in glucosylceramide (GlcCer) level. Mechanistic studies revealed that D-PDMP inhibited cell proliferation and angiogenesis by inhibiting p44MAPK, p-AKT-1 pathway and mammalian target for rapamycin (mTOR). By linking glycosphingolipid synthesis with tumor growth, renal cancer progression and regression can be evaluated. Thus inhibiting glycosphingolipid synthesis can be a bonafide target to prevent the progression of other types of cancer.

UR - http://www.scopus.com/inward/record.url?scp=84877348060&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84877348060&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0063726

DO - 10.1371/journal.pone.0063726

M3 - Article

C2 - 23671696

AN - SCOPUS:84877348060

VL - 8

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 5

M1 - e63726

ER -